Pharma News

The Japanese Ministry of Health, Labor, and Welfare (MHLW) has granted marketing authorization for Xenpozyme  (olipudase alfa) for the treatment of adult and pediatric patients with non-central nervous system (non-CNS) manifestations of acid sphingomyelinase deficiency (ASMD), a rare, progressive, and potentially life-threatening genetic disease.

Pharma Giant Pfizer recalls blood pressure medicines, brand name as Accuretic from the US market over presence of cancer causing impurities. Accuretic is a combination of quinapril HCl and hydrochlorothiazide.

Abbott received permission from the Subject Expert Committee to market a fixed dose combination (FDC) of Lidocaine and Diltiazem, after detailed deliberation by committee.

Abbott has presented a Phase III clinical trial report before the committee and after detailed deliberation, the committee recommended grant of permission for manufacturing and marketing of the proposed FDC.

Indoco Remedies Ltd. announces final approval from the United States Food and Drug Administration (USFDA) for Lacosamide Tablets USP 50 mg, 100 mg, 150 mg and 200 mg, the generic version of Vimpat Tablets of UCB, Inc.

Lacosamide Tablets are indicated for the prevention and control of seizures. It is an anticonvulsant / antiepileptic drug.

Novavax, Inc a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, and Serum Institute of India Pvt. Ltd. (SII), the worlds largest vaccine manufacturer by volume, announced that the Drugs Controller General of India has granted emergency use authorization (EUA) for Novavax protein-based COVID-19 vaccine for adolescents aged ≥12 to <18 years in India.

Short term use of oral benzodiazepines, BZDs, for periprocedural anxiolysis seems to be safe and effective. The 2020 FDA black-box warning should not deter their appropriate use in dermatologic surgery and other low-risk outpatient procedures, says recent research from Ohio State University.

Children previously infected with COVID-19 develop natural circulating antibodies that last for at least seven months, according to a new study led by researchers at UTHealth Houston.

The study was published today in Pediatrics.
Researchers examined data from 218 children across the state of Texas between the ages of 5 and 19 who were enrolled in the Texas CARES survey, which began in October of 2020 with the goal of assessing COVID-19 antibody status over time among a population of adults and children in Texas.

A study has found that much higher doses of antibiotics are needed to eliminate a bacterial infection of the airways when other microbes are present. It helps explain why respiratory infections often persist in people with lung diseases such as cystic fibrosis despite treatment.